Daratumumab-containing regimens are recommended as treatment options by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)*†‡
NCCN Guidelines® recommendations in newly diagnosed multiple myeloma
NCCN Guidelines preferred regimen for
non-transplant candidates‡
DRd: daratumumab (D), lenalidomide (R), and dexamethasone (d) (Category 1) primary therapy
NCCN Guidelines other recommended regimen for non-transplant candidates‡
DVMP: daratumumab (D), bortezomib (V), melphalan (M), and prednisone (P)(Category 1) primary therapy
NCCN Guidelines useful in certain circumstances for transplant candidates‡
DVTd: daratumumab (D), bortezomib (V), thalidomide (T), and dexamethasone(d) (Category 2A) primary therapy
NCCN Guidelines recommendations in relapsed or refractory multiple myeloma
NCCN Guidelines preferred regimens for early relapses (1-3 prior therapies)‡
DRd: daratumumab (D), lenalidomide (R), and dexamethasone (d) (Category 1)
DVd: daratumumab (D), bortezomib (V), and dexamethasone (d) (Category 1)
DKd: daratumumab (D), carfilzomib (K), and dexamethasone (d) (Category 1)
After 2 prior therapies including lenalidomide and a PI DPd: daratumumab (D), pomalidomide (P), and dexamethasone (d)§ (Category 1)
Useful in certain circumstances‡
After at least 3 prior therapies including a PI and an immunomodulatory agent or are
double refractory to a PI and an immunomodulatory agentDaratumumab (Category 2A)
PI=proteasome inhibitor.
*Daratumumab includes both daratumumab (DARZALEX®) for intravenous infusion and daratumumab and
hyaluronidase-fihj (DARZALEX FASPRO®) for subcutaneous injection. Daratumumab and hyaluronidase-fihj for subcutaneous
injection has different dosing and administration instructions compared to
daratumumab for intravenous infusion.
†See nccn.org for definitions of NCCN Categories of Preference and NCCN Categories of
Evidence and Consensus.
‡Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology
(NCCN Guidelines®)for Multiple Myeloma V3.2023.
© National Comprehensive Cancer Network, Inc. 2022. All rights reserved.
Accessed December 12, 2022. To view the most recent and complete version of the
guideline, go online to www.nccn.org. NCCN makes no warranties of any
kind whatsoever regarding their content, use or application and disclaims any
responsibility for their application or use in any way.
§DARZALEX FASPRO®+ Pd is FDA-approved in patients who have received ≥1 prior line of therapy including
lenalidomide and a proteasome inhibitor (PI). DARZALEX®+ Pd is FDA-approved in patients who have received ≥2 prior lines of therapy including lenalidomide
and a PI.
DARZALEX®
and DARZALEX FASPRO®
studied in wide range of clinical trials for multiple myeloma